Drug intelligence / Profile preview

lactobacillus plantarum DP189

Development stage: Preclinical
Lead developer: Northeast Agricultural University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus plantarum DP189 is a specific probiotic strain, recently reclassified as *Lactiplantibacillus plantarum* DP189, that is being researched for its potential to treat neurodegenerative disorders, specifically Parkinson's disease. Preclinical studies demonstrate that DP189 can cross the gut-brain axis to reduce the accumulation of alpha-synuclein (α-SYN) aggregates in the substantia nigra. Its mechanism of action involves the activation of the Nrf2/ARE and PGC-1α antioxidant signaling pathways, which increases the production of protective enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Simultaneously, it suppresses the NLRP3 inflammasome and reduces the levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. Furthermore, DP189 modulates the gut microbiota by decreasing pathogenic bacteria and increasing beneficial probiotic populations.

Other names: L. plantarum DP189Lactiplantibacillus plantarum DP189

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)SNCA (Alpha-synuclein)PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)

Beyond the preview

Go deeper on lactobacillus plantarum DP189.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum DP189.

Explore the full profile